Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UK-369,003 in COPD
NCT00163098Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing UK-369,003 with Placebo (2 arms). Primary endpoint: Exercise tolerance. Started Dec 2004; status: completed.
02
Drugs
gisadenafil besylate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00163098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00163098.